Two other clinical trials are studying the toxicity and efficiency of a DNA vaccine coding for the HER2 intracellular domain when given together with GM-CSF (ClinicalTrials.gov, NCT00436254) or before immunization with a vaccine made from HER2/neu protein (ClinicalTrials.gov, NCT00363012) in patients with stage III-IV breast cancer or ovarian cancer. This evidence concerns the gene ERBB2 and breast carcinoma.